The second phase of the orientation workshop is being organized to provide in-depth knowledge to the state officials on core building blocks of ABDM
Scemblix (asciminib) continues to show superior efficacy with more-than-two-fold improvement in major molecular response rate vs. Bosulif (bosutinib) at 96 weeks
The dashboard will serve as a single source of truth for public and PM-JAY stakeholders providing comprehensive view of scheme’s progress
The DMF#36513 demonstrates ANP’s success in the development of its “Plug and Play” drug delivery platform.
Immune-mediated events and infusion reactions were higher with KEYTRUDA (38% vs 9%, respectively).
PharmaLytica Expo to aid in chalking out pharma industry’s $130 Billion growth story by 2030
Innate to receive $5M milestone payment from AstraZeneca
Radicava ORS was approved by the U.S. Food and Drug Administration (FDA) on May 12, 2022
Besides enhancing workflow operations by connecting scientists with their lab instruments and data, digitalization holds the potential to acceleratee long-term business growth
Dupixent would be the first and only medicine specifically indicated to treat prurigo nodularis in the U.S., if approved
Subscribe To Our Newsletter & Stay Updated
